Revoke Mylan’s Corporate Charter
Something needs to be done to stop the price gouging by the pharmaceutical industry. Perhaps this would be a good place to start.
By now, you’ve probably heard about Mylan Laboratories’ massive price hikes in the EpiPen, which is used to treat life-threatening allergic reactions. You might have even heard how the EpiPen technology is entirely the result of federally funded research. Perhaps you even read about the possible (who are we kidding, probable) anti-trust violations that Mylan has committed. But this is simply par for the course (boldface mine):
EpiPen price hikes may be causing outrage, but those pale in comparison to the huge increases that Mylan Laboratories took on dozens of other medicines earlier this year.
For instance, the company raised the price of ursodiol, a generic medicine used to treat gallstones, by 542 percent. There was also a 400 percent boost in the price for dicyclomine, which combats irritable bowel syndrome, and a 312 percent increase for metoclopramide, a generic drug that treats gastroesophageal reflux disease.
View original post 352 more words